MedTrace Logo

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis

NCT00118703 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2017-08-21

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with vasomotor rhinitis (VMR).

Conditions

  • Vasomotor Rhinitis
  • Rhinitis, Vasomotor

Interventions

DRUG

GW685698X

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-01
Primary Completion
2006-02-01
Completion
2006-02-09

Countries

  • United States
  • Canada
  • Czechia
  • Germany
  • Norway
  • Puerto Rico
  • Romania

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00118703 on ClinicalTrials.gov